The prescribing information for Nubeqa (darolutamide) — used to treat men with prostate cancer that has not spread to other parts of the body — will be updated to include overall survival data for patients with non-metastatic castration-resistant prostate cancer (nmCRPC), according to Bayer, one of the therapy’s developers. Specifically, data demonstrating that Nubeqa lowers the risk of death by 31% in nmCRPC will now be included in the prescribing information, Bayer announced. In addition,…

You must be logged in to read/download the full post.